Catabasis Pharmaceuticals Inc. today announced the upcoming presentation of clinical and preclinical data for its lead candidate, CAT-2003, further defining its mechanism of action in the treatment of severe hypertriglyceridemia and chylomicronemia syndromes. Data from the Phase 1 study of CAT-2003 will be presented in an oral session at the National Lipid Association (NLA) Scientific Sessions 2014 in Orlando, FL, and preclinical data will be presented in one oral session and one poster session at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2014 Scientific Sessions in Toronto, Ontario.
Help employers find you! Check out all the jobs and post your resume.
